Bio-Techne Corporation (NasdaqGS:TECH) is rolling out a new brand architecture centered on three portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The updated structure ...
A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.
Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
Christine Willett is a Senior Manager of Quality in the Diagnostics division at Bio-Techne, overseeing quality operations at ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results